MSD is preparing to take on Takeda in the dengue fever vaccine market, moving its V181 candidate into phase 3.

MSD expects to see an additional $200m layered onto its costs this year as a result of President Trump's tariffs, ahead of any pharma-specific levy.

Hitachi plans to invest $1 billion to expand its U.S. power grid infrastructure manufacturing, its energy unit said on Thursday, as the country faces record electricity demand from Big Tech's ...